On 19 September 2019, Eurosurveillance published a rapid communication led by Public Health England (PHE), highlighting two new variants of Chlamydia trachomatis (CT) escaping detection by the Aptima Combo 2 (AC2) assay in England between June and August 2019. These variants were identified in the clinical specimens of two patients, of which one had a C1514T mutation and the other a G1523A mutation. The prevalence of such variants among persons tested for CT in England was estimated to be less than 0.003%.
In Scotland, the single laboratory which uses this AC2-CT assay tested 3,023 samples for CT during the same period referred to in the PHE communication. Of the chlamydia negatives recorded, 62 were re-tested on the ACT assay. Three samples gave discrepant results and were sequenced by the World Health Organization Collaborating Centre for Gonorrhoea and Other STIs at Örebro University in Sweden, no mutations were identified. Thus, there is no evidence of these chlamydia variants being present in the Scottish population at this point in time.
Source: Eurosurveillance, 19 September 2019